Now live: Pro — the full 13F research suite for serious investorsSee pricing →
EcoR1 Capital, LLC

Q1 2024 · 13F-HR

EcoR1 Capital, LLCholdings as filed

Filed 2024-05-15 · accession 0000935836-24-000391

$3.95B
Reported value
59
Positions
2024-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
03753U106APLSUSDAPELLIS PHARMACEUTICALS INC$667.6M16.9%11,357,425CommonSOLE
G72800108PRTAPROTHENA CORP PLC$286.9M7.26%11,584,280CommonSOLE
04335A105ARVNARVINAS INC$277.7M7.02%6,726,491CommonSOLE
803607100SRPTSAREPTA THERAPEUTICS INC$248.5M6.29%1,919,835CommonSOLE
22663K107CRNXCRINETICS PHARMACEUTICALS IN$194.5M4.92%4,155,375CommonSOLE
36315X101LKFTGALAPAGOS NV$185.4M4.69%5,756,268CommonSOLE
032724106ANABANAPTYSBIO INC$169.4M4.28%7,521,024CommonSOLE
98985Y108ZYMEZYMEWORKS INC$141.4M3.58%13,437,473CommonSOLE
50127T109KURAKURA ONCOLOGY INC$123.9M3.13%5,806,871CommonSOLE
G50871105JAZZJAZZ PHARMACEUTICALS PLC$122.1M3.09%1,013,952CommonSOLE
98401F105XNCRXENCOR INC$118.0M2.98%5,330,416CommonSOLE
004225108ACADACADIA PHARMACEUTICALS INC$110.8M2.80%5,991,479CommonSOLE
87583X109TNGXTANGO THERAPEUTICS INC$105.8M2.68%13,330,736CommonSOLE
45257U108IMNMIMMUNOME INC$95.7M2.42%3,879,415CommonSOLE
H17182108CRSPCRISPR THERAPEUTICS AG$94.7M2.40%1,389,276CommonSOLE
59045L106MERSANA THERAPEUTICS INC$86.8M2.19%19,364,688CommonSOLE
61775R105MORFUSDMORPHIC HLDG INC$83.9M2.12%2,384,384CommonSOLE
67080N101NUVBNUVATION BIO INC$69.9M1.77%19,209,643CommonSOLE
64135M105NGNENEUROGENE INC$64.7M1.64%1,271,342CommonSOLE
152309100CNTACENTESSA PHARMACEUTICALS PLC$63.5M1.61%5,618,779CommonSOLE
68622P109ORICORIC PHARMACEUTICALS INC$47.0M1.19%3,418,068CommonSOLE
00653A107ADAPYADAPTIMMUNE THERAPEUTICS PLC$43.3M1.10%27,404,070CommonSOLE
89854M101TCRXTSCAN THERAPEUTICS INC$39.7M1.00%5,000,000CommonSOLE
92915B106VYGRVOYAGER THERAPEUTICS INC$36.5M0.92%3,917,546CommonSOLE
88427A107THIRD HARMONIC BIO INC$30.0M0.76%3,182,444CommonSOLE
640979100NMRANEUMORA THERAPEUTICS INC.$28.5M0.72%2,071,450CommonSOLE
15117B202CLDXCELLDEX THERAPEUTICS INC$27.3M0.69%650,000CommonSOLE
46565G1045E7ITEOS THERAPEUTICS INC$27.3M0.69%1,999,249CommonSOLE
52635N103LENZLENZ THERAPEUTICS INC$27.2M0.69%1,219,774CommonSOLE
04683R106AVIRATEA PHARMACEUTICALS INC$24.8M0.63%6,145,861CommonSOLE
014442107ALECALECTOR INC$24.4M0.62%4,056,548CommonSOLE
28036F105EWTXEDGEWISE THERAPEUTICS INC$22.8M0.58%1,250,385CommonSOLE
65487U108NKTXNKARTA INC$21.6M0.55%2,000,000CommonSOLE
N69605108PHVSPHARVARIS N V$20.8M0.53%900,000CommonSOLE
92243G108PCVXVAXCYTE INC$20.5M0.52%300,000CommonSOLE
558868105MDGLMADRIGAL PHARMACEUTICALS INC$20.0M0.51%75,000CommonSOLE
05370A108RNAGBPAVIDITY BIOSCIENCES INC$19.3M0.49%757,576CommonSOLE
690469101OVIDOVID THERAPEUTICS INC$18.7M0.47%6,117,400CommonSOLE
92539P101VERVE THERAPEUTICS INC$16.6M0.42%1,250,000CommonSOLE
50127T109KURAKURA ONCOLOGY INC$14.9M0.38%700,000CALLSOLE
492327101KROSKEROS THERAPEUTICS INC$12.4M0.31%187,500CommonSOLE
26818M108DYNDYNE THERAPEUTICS INC$12.1M0.31%427,039CommonSOLE
501976104KYTXKYVERNA THERAPEUTICS INC$11.2M0.28%450,000CommonSOLE
38341P102GOSSGOSSAMER BIO INC$10.9M0.27%9,195,404CommonSOLE
019818103ALLOVIR INC$8.5M0.22%11,294,585CommonSOLE
50015M109KODKODIAK SCIENCES INC$8.5M0.21%1,613,600CommonSOLE
37148K100GBIOGBXGENERATION BIO CO$8.3M0.21%2,046,867CommonSOLE
046513107ATRAGBXATARA BIOTHERAPEUTICS INC$7.1M0.18%10,167,043CommonSOLE
N71542109PRQRPROQR THRAPEUTICS N V$6.6M0.17%2,884,357CommonSOLE
01626L105ALIGOS THERAPEUTICS INC$6.3M0.16%6,389,468CommonSOLE
03969K108ARQTARCUTIS BIOTHERAPEUTICS INC$5.0M0.13%500,000CommonSOLE
74168J101PRMEPRIME MEDICINE INC$4.9M0.12%700,000CommonSOLE
67080N119NUVB/WSNUVATION BIO INC$3.5M0.09%963,333CommonSOLE
43906K100HOOKGBPHOOKIPA PHARMA INC$3.3M0.08%4,595,024CommonSOLE
86889P117SRZNWSURROZEN INC$1.0M0.03%66,665CommonSOLE
69353Y103PMVPPMV PHARMACEUTICALS INC$963,6940.02%566,879CommonSOLE
14171W111CAREMAX INC$482,0000.01%100,000CommonSOLE
50015M109KODKODIAK SCIENCES INC$268,7860.01%51,100CALLSOLE
02083G100NVLSEURALPINE IMMUNE SCIENCES INC$39,6400.00%1,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.